IMAC Holdings Files S-1/A Amendment

TL;DR

IMAC Holdings filed an S-1/A, likely for a stock offering or update. Keep an eye on this.

AI Summary

IMAC Holdings, Inc. filed an S-1/A amendment on January 24, 2025, for its registration statement. The company, incorporated in Delaware, operates in specialty outpatient facilities and is headquartered in Franklin, Tennessee. This filing is an amendment to a previous S-1 registration statement.

Why It Matters

This S-1/A filing indicates that IMAC Holdings, Inc. is actively pursuing a securities offering or making significant updates to its registration, which could impact its capital structure and future operations.

Risk Assessment

Risk Level: medium — S-1/A filings often relate to capital raises or significant corporate changes, which inherently carry risks for investors.

Key Numbers

• 333-280184 — SEC File Number (Identifies the specific registration filing with the SEC.)
• 25555288 — Film Number (Internal SEC processing number for the filing.)

Key Players & Entities

• IMAC Holdings, Inc. (company) — Registrant
• January 24, 2025 (date) — Filing Date
• 333-280184 (registration_number) — SEC File Number
• Delaware (jurisdiction) — State of Incorporation
• Franklin, Tennessee (location) — Principal Executive Offices
• Faith Zaslavsky (person) — Chief Executive Officer

FAQ

Key Financial Figures

• $0.001 — 7,025 shares of common stock, par value $0.001 per share, or common stock. The shares
• $1 million — change Commission, or the SEC, and (ii) $1 million of shares of common stock (769,231 shar
• $1.30 — mon stock assuming a price per share of $1.30), or the Back-End Commitment Shares (an
• $60 million — rice (as defined below) and (iii) up to $60 million of shares of common stock (or up to the
• $0.78 — Stock on the Nasdaq Capital Market was $0.78 per share. We are a “smaller re
• $1,000,000 — from the Company up to an aggregate of $1,000,000 with an initial borrowing on April 12,
• $350,000 — initial borrowing on April 12, 2024 of $350,000 (the “Theralink Credit Agreement&
• $900,000 — ted in gross proceeds to the Company of $900,000. On April 30, 2024, we entered into s
• $16,221,873.89 — gregate principal amount outstanding of $16,221,873.89 and which the Theralink Note Holders ac
• $3,000,000 — gregate outstanding principal amount of $3,000,000 (the “Pre-Existing Theralink Note
• $450,000 — n stock, for aggregate cash proceeds of $450,000. On June 18, 2024, we issued promisso
• $1,400,000 — rs in the aggregate principal amount of $1,400,000, for an aggregate purchase price from t
• $840,000 — rs in the aggregate principal amount of $840,000, for an aggregate purchase price from t
• $600,000 — gate purchase price from the Lenders of $600,000. The September-October 2024 Notes are u

Filing Documents

• forms-1a.htm (S-1/A) — 593KB
• ex5-1.htm (EX-5.1) — 15KB
• ex23-1.htm (EX-23.1) — 5KB
• ex23-2.htm (EX-23.2) — 5KB
• ex107.htm (EX-FILING FEES) — 20KB
• forms-1a_001.jpg (GRAPHIC) — 5KB
• ex5-1_001.jpg (GRAPHIC) — 7KB
• ex5-1_002.jpg (GRAPHIC) — 3KB
• 0001493152-25-003655.txt ( ) — 659KB

RISK FACTORS

RISK FACTORS 9 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 12 THE COMMITTED EQUITY FINANCING 13

USE OF PROCEEDS

USE OF PROCEEDS 18 DIVIDEND POLICY 19 SELLING STOCKHOLDER 20

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 21 PLAN OF DISTRIBUTION 31 LEGAL MATTERS 33 EXPERTS 33 WHERE YOU CAN FIND MORE INFORMATION 34 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET 35 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 36 ABOUT THIS PROSPECTUS The registration statement of which this prospectus forms a part, or the Registration Statement, includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus, the related exhibits to the Registration Statement filed with the Securities and Exchange Commission, or the SEC, and the documents incorporated by reference herein before making your investment decision. You should rely only on the information provided in this prospectus and the documents incorporated by reference herein or any amendment thereto. You should not assume that the information contained in this prospectus or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference herein or therein is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus or any related free writing prospectus is delivered, or securities are sold, on a later date. This prospectus contains or incorporates by reference summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been or will be filed or have been or will be incorporated by reference as exhibits to the registration statement of which this prospectus forms a part, and you may obtain copies of those documents as described in this prospectus under the heading “Where You Can Find More Information.” You should rely only

View Full Filing

View this S-1/A filing on SEC EDGAR